Lifevantage Corp LFVN
LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We sell our products in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland, and Portugal. We also sell our products in a number of countries to customers for personal consumption only.
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $182.6M | $228.5M | $200.2M | $213.4M | $206.4M | $220.2M | $232.9M | $226.0M | $203.2M | $199.5M |
| Cost of revenue | $41.0M | $44.9M | $41.4M | $43.4M | $38.1M | $38.2M | $38.0M | $38.0M | $34.8M | $33.5M |
| Gross profit | $141.6M | $183.7M | $158.7M | $170.0M | $168.3M | $182.0M | $195.0M | $188.0M | $168.4M | $166.0M |
| R&D | $1.0M | $1.4M | $700.0K | $600.0K | $700.0K | $700.0K | $900.0K | $1.1M | $1.2M | $1.1M |
| SG&A | $58.4M | $69.2M | $68.5M | $71.1M | $63.4M | $60.8M | $67.9M | $69.6M | $59.8M | $64.9M |
| Total operating expenses | $135.5M | $171.5M | $154.4M | $165.8M | $160.7M | $164.4M | $179.5M | $178.2M | $158.0M | $161.6M |
| Operating income | $6.1M | $12.2M | $4.3M | $4.3M | $7.6M | $17.6M | $15.5M | $9.8M | $10.3M | $4.4M |
| Interest expense | — | — | $430.0K | $198.0K | $10.0K | $17.0K | $120.0K | $323.0K | $456.0K | $570.0K |
| Pre-tax income | $6.1M | $12.2M | $4.3M | $4.0M | $4.7M | $17.2M | $14.7M | $9.2M | $9.5M | $2.9M |
| Income tax | $994.0K | $2.4M | $1.4M | $1.5M | $1.6M | $4.3M | $3.1M | $1.8M | $3.8M | $1.3M |
| Net income | $5.1M | $9.8M | $2.9M | $2.5M | $3.1M | $12.9M | $11.5M | $7.4M | $5.8M | $1.6M |
| EPS, basic | 0.40 | 0.80 | 0.24 | 0.20 | 0.24 | 0.92 | 0.82 | 0.53 | 0.41 | 0.12 |
| EPS, diluted | 0.40 | 0.75 | 0.23 | 0.20 | 0.24 | 0.90 | 0.79 | 0.50 | 0.41 | 0.11 |
| Shares, diluted (wtd. avg.) | $12.7M | $13.0M | $13.0M | $12.6M | $13.1M | $14.3M | $14.6M | $15.0M | $14.1M | $14.1M |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.9M | $20.2M | $16.9M | $21.6M | $20.2M | $23.2M | $22.1M | $18.8M | $16.7M | $11.5M |
| Receivables | $3.0M | $3.3M | $2.9M | $1.6M | $3.3M | $2.9M | $2.6M | $2.1M | $2.1M | $1.3M |
| Inventory | $16.2M | $20.7M | $15.1M | $16.1M | $16.5M | $16.1M | $13.9M | $13.8M | $13.6M | $16.6M |
| Total current assets | $38.3M | $50.9M | $37.6M | $44.3M | $47.0M | $48.1M | $43.9M | $43.2M | $38.9M | $35.5M |
| Property, plant and equipment | $7.3M | $6.2M | $7.8M | $9.1M | $9.5M | $11.1M | $7.2M | $7.1M | $6.6M | $3.1M |
| Goodwill | $465.0K | $0 | — | — | — | — | — | — | — | — |
| Other intangibles | $3.1M | $245.0K | $323.0K | $455.0K | $587.0K | $719.0K | $851.0K | $983.0K | $1.1M | $1.2M |
| Total assets | $62.1M | $72.0M | $60.3M | $66.1M | $70.7M | $78.7M | $58.9M | $55.3M | $51.1M | $45.2M |
| Accounts payable | $5.2M | $4.6M | $5.9M | $3.5M | $7.5M | $6.7M | $3.5M | $5.2M | $3.8M | $4.8M |
| Short-term debt | — | — | — | — | — | — | $0 | $1.5M | $2.0M | $2.0M |
| Total current liabilities | $20.2M | $27.2M | $22.3M | $19.6M | $25.7M | $25.2M | $25.0M | $26.2M | $23.8M | $23.4M |
| Long-term debt | — | — | — | — | — | — | — | $0 | $3.4M | $5.4M |
| Total liabilities | $28.5M | $37.3M | $34.3M | $31.5M | $39.2M | $41.9M | $25.6M | $28.1M | $29.2M | $30.7M |
| Retained earnings | -$103.5M | -$104.1M | -$108.7M | -$98.3M | -$98.4M | -$92.3M | -$93.3M | -$100.0M | -$102.7M | -$107.0M |
| Total equity | $33.6M | $34.6M | $26.0M | $34.6M | $31.5M | $36.8M | $33.3M | $27.2M | $21.9M | $14.5M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.2M | $11.9M | $12.2M | $6.8M | $8.0M | $16.3M | $18.3M | $17.8M | $13.3M | $6.6M |
| Depreciation and amortisation | $2.8M | $3.2M | $3.6M | $3.6M | $3.3M | $3.5M | $2.8M | $1.9M | $1.3M | $1.6M |
| Stock-based compensation | $2.3M | $5.7M | $3.3M | $3.2M | $1.8M | $2.0M | $4.9M | $5.5M | $3.2M | $2.6M |
| Capital expenditure | $3.6M | $1.4M | $2.2M | $3.1M | $1.5M | $3.7M | $2.7M | $2.5M | $4.6M | $1.1M |
| Investing cash flow | -$7.3M | -$1.4M | -$2.2M | -$3.1M | -$1.5M | -$3.7M | -$2.7M | -$4.5M | -$4.6M | -$1.1M |
| Financing cash flow | -$7.8M | -$7.6M | -$14.4M | -$2.4M | -$9.0M | -$11.5M | -$12.4M | -$11.1M | -$3.5M | -$2.0M |
| Dividends paid | $2.3M | $2.1M | $6.9M | $1.6M | $378.0K | $0 | $0 | — | — | — |
| Buybacks | $2.0M | $3.1M | $6.4M | $822.0K | $8.8M | $11.9M | $5.4M | $4.7M | $1.5M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-371257.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |